Senator Investment Group LP Purchases Shares of 200,000 Danaher Corporation $DHR

Senator Investment Group LP bought a new stake in shares of Danaher Corporation (NYSE:DHR) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 200,000 shares of the conglomerate’s stock, valued at approximately $41,000,000. Danaher accounts for approximately 2.2% of Senator Investment Group LP’s investment portfolio, making the stock its 20th biggest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FAS Wealth Partners Inc. boosted its position in shares of Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock valued at $2,203,000 after purchasing an additional 1,639 shares in the last quarter. MGO One Seven LLC boosted its position in shares of Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new stake in shares of Danaher during the 1st quarter valued at about $539,000. Horizon Financial Services LLC boosted its position in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Finally, EFG Asset Management Americas Corp. boosted its position in shares of Danaher by 13.1% during the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate’s stock valued at $7,396,000 after purchasing an additional 4,191 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $209.32 on Tuesday. The company has a market cap of $149.88 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The business has a 50 day moving average price of $200.14 and a 200-day moving average price of $199.45. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. Danaher’s revenue was up 3.4% on a year-over-year basis. During the same period last year, the business posted $1.72 earnings per share. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on DHR shares. Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Robert W. Baird upped their price target on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research note on Friday, July 18th. Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $247.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.